Risks of androgen therapy

Nieschlag, 2005, Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations, Int J Androl, 28, 125, 10.1111/j.1365-2605.2005.00553.x Kaufman, 2005, The decline of androgen levels in elderly men and its clinical and therapeutic implications, Endocr Rev, 26, 833, 10.1210/er.2004-0013 Bhasin, 2006, Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline, J Clin Endocrinol Metab, 91, 1995, 10.1210/jc.2005-2847 Hijazi, 2005, Andropause: is androgen replacement therapy indicated for the aging male?, Annu Rev Med, 56, 117, 10.1146/annurev.med.56.082103.104518 Behre, 1994, Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls, Clin Endocrinol (Oxf), 40, 341, 10.1111/j.1365-2265.1994.tb03929.x Jin, 2001, Effects of androgen deficiency and replacement on prostate zonal volumes, Clin Endocrinol (Oxf), 54, 437, 10.1046/j.1365-2265.2001.01240.x Schultheiss, 2004, Testosterone therapy in the ageing male: what about the prostate?, Andrologia, 36, 355, 10.1111/j.1439-0272.2004.00630.x Morales, 2004, Testosterone treatment for the aging man: the controversy, Curr Urol Rep, 5, 472, 10.1007/s11934-004-0073-z Severi, 2006, Circulating steroid hormones and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 15, 86, 10.1158/1055-9965.EPI-05-0633 Rhoden, 2004, Risks of testosterone-replacement therapy and recommendations for monitoring, N Engl J Med, 350, 482, 10.1056/NEJMra022251 Calof, 2005, Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials, J Gerontol A Biol Sci Med Sci, 60, 1451, 10.1093/gerona/60.11.1451 Rhoden, 2003, Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia, J Urol, 170, 2348, 10.1097/01.ju.0000091104.71869.8e Kaufman, 2004, Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men, J Urol, 172, 920, 10.1097/01.ju.0000136269.10161.32 Kaufman, 2006, A rational approach to androgen therapy for hypogonadal men with prostate cancer, Int J Impot Res, 18, 26, 10.1038/sj.ijir.3901401 Gaylis, 2005, Prostate cancer in men using testosterone supplementation, J Urol, 174, 534, 10.1097/01.ju.0000165166.36280.60 Nam, 2003, Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy, Can J Urol, 10, 1891 Graefen, 2005, Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?, Eur Urol, 47, 756, 10.1016/j.eururo.2005.02.004 Khan, 2004, Impact of surgical delay on long-term cancer control for clinically localized prostate cancer, J Urol, 172, 1835, 10.1097/01.ju.0000140277.08623.13 Boorjian, 2005, Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?, BJU Int, 96, 773, 10.1111/j.1464-410X.2005.05763.x Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0ngper millilitre, N Engl J Med, 350, 2239, 10.1056/NEJMoa031918 Kundu, 2005, Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2ng/ml, J Urol, 173, 1116, 10.1097/01.ju.0000155460.20581.a4 Gooren, 2004, Androgen replacement therapy: present and future, Drugs, 64, 1861, 10.2165/00003495-200464170-00002 Shahidi, 1973, Androgens and erythropoiesis, N Engl J Med, 289, 72, 10.1056/NEJM197307122890205 Drinka, 1995, Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels, J Am Geriatr Soc, 43, 899, 10.1111/j.1532-5415.1995.tb05534.x Jockenhovel, 1997, Effects of various modes of androgen substitution therapy on erythropoiesis, Eur J Med Res, 2, 293 Hajjar, 1997, Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis, J Clin Endocrinol Metab, 82, 3793, 10.1210/jc.82.11.3793 Sih, 1997, Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial, J Clin Endocrinol Metab, 82, 1661, 10.1210/jc.82.6.1661 Schubert, 2004, Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism, J Clin Endocrinol Metab, 89, 5429, 10.1210/jc.2004-0897 Grunstein, 1989, Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy, J Clin Endocrinol Metab, 68, 352, 10.1210/jcem-68-2-352 Liu, 2003, The short-term effects of high-dose testosterone on sleep, breathing, and function in older men, J Clin Endocrinol Metab, 88, 3605, 10.1210/jc.2003-030236 Matsumoto, 1985, Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep, Clin Endocrinol (Oxf), 22, 713, 10.1111/j.1365-2265.1985.tb00161.x Van Pottelbergh, 2003, Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men, Atherosclerosis, 166, 95, 10.1016/S0021-9150(02)00308-8 Hak, 2002, Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study, J Clin Endocrinol Metab, 87, 3632, 10.1210/jc.87.8.3632 Kupelian, 2006, Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men, J Clin Endocrinol Metab, 91, 843, 10.1210/jc.2005-1326 Singh, 2002, The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men, J Clin Endocrinol Metab, 87, 136, 10.1210/jc.87.1.136 Whitsel, 2001, Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis, Am J Med, 111, 261, 10.1016/S0002-9343(01)00833-6 Snyder, 2001, Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age, Am J Med, 111, 255, 10.1016/S0002-9343(01)00813-0 Dobs, 1999, Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men, J Clin Endocrinol Metab, 84, 3469, 10.1210/jc.84.10.3469 Page, 2005, Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T, J Clin Endocrinol Metab, 90, 1502, 10.1210/jc.2004-1933 Isidori, 2005, Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis, Clin Endocrinol (Oxf), 63, 280, 10.1111/j.1365-2265.2005.02339.x Wu, 2003, Androgens and coronary artery disease, Endocr Rev, 24, 183, 10.1210/er.2001-0025 Liu, 2003, Androgens and cardiovascular disease, Endocr Rev, 24, 313, 10.1210/er.2003-0005 Shabsigh, 2005, Cardiovascular issues in hypogonadism and testosterone therapy, Am J Cardiol, 96, 67M, 10.1016/j.amjcard.2005.10.009 Smith, 2005, Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina, Eur J Endocrinol, 152, 285, 10.1530/eje.1.01848 Malkin, 2006, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial, Eur Heart J, 27, 57, 10.1093/eurheartj/ehi443